Study #2021-0981
A Multicenter, Randomized, Open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
MD Anderson Study Status
Not Accepting
Treatment Agent
Abelacimab, Apixaban
Description
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Study phase:
Phase III
Physician name:
Cristhiam Rojas Hernandez
Department:
Benign Hematology
For general questions about clinical trials:
1-844-317-6206
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.